POET TECHNOLOGIES (POETF) Analysts See $-0.01 EPS; Kamada Limited Ord (KMDA) Shorts Lowered By 4.72%

November 15, 2017 - By Hazel Jackson

Analysts expect POET TECHNOLOGIES (OTCMKTS:POETF) to report $-0.01 EPS on November, 27.After having $-0.01 EPS previously, POET TECHNOLOGIES’s analysts see 0.00% EPS growth. The stock decreased 3.92% or $0.008 on November 14, reaching $0.194. About 15,500 shares traded. POET TECHNOLOGIES (OTCMKTS:POETF) has 0.00% since November 15, 2016 and is . It has underperformed by 16.70% the S&P500.

Kamada Limited Ord (NASDAQ:KMDA) had a decrease of 4.72% in short interest. KMDA’s SI was 109,100 shares in November as released by FINRA. Its down 4.72% from 114,500 shares previously. With 62,800 avg volume, 2 days are for Kamada Limited Ord (NASDAQ:KMDA)’s short sellers to cover KMDA’s short positions. The SI to Kamada Limited Ord’s float is 0.39%. The stock increased 4.30% or $0.2 on November 14, reaching $4.85. About shares traded. Kamada Ltd (NASDAQ:KMDA) has risen 73.86% since November 15, 2016 and is uptrending. It has outperformed by 57.16% the S&P500.

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. The company has market cap of $169.36 million. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. It currently has negative earnings. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com